Abivax (AAVXF) Cash & Equivalents (2021 - 2026)

Abivax has reported Cash & Equivalents for 6 years, with the latest figure at $558.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 413.03% year-over-year to $558.9 million in Q1 2026; TTM through Mar 2026 was $558.9 million, a 413.03% increase from a year earlier, with the FY2025 full-year figure at $601.4 million, up 290.26% from the prior year.
• Cash & Equivalents was $558.9 million for Q1 2026 at Abivax, down from $601.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $689.4 million in Q3 2025, with the low at $27.5 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $289.1 million, with a median of $239.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 885.88% in 2023, then tumbled 71.18% in 2025.
• Over 5 years, Cash & Equivalents stood at $27.5 million in 2022, then surged by 885.88% to $271.1 million in 2023, then tumbled by 43.15% to $154.1 million in 2024, then surged by 290.26% to $601.4 million in 2025, then declined by 7.07% to $558.9 million in 2026.
• The last three Cash & Equivalents figures came in at $558.9 million (Q1 2026), $601.4 million (Q4 2025), and $689.4 million (Q3 2025), per Business Quant data.